PharmiWeb Recruiter Blog

As 2023 draws to a close, we wanted to take a moment to express our gratitude for your support during what has been a challenging year for the life science industry.

Healthcare intelligence organisation earns recognition as employer of choice and leading innovator in the clinical trial industry

• Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer
• To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio^® (avelumab) in the U.S. to the American Association for Cancer Research (AACR)

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.

Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases

• A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Heidelberg, November 7, 2023. BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.

• Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets
• Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities
• Under the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 million

Basel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

Strengthening your employer brand through thought leadership is valuable for several reasons. Firstly, it will allow your organisation to establish itself as a trusted authority in the life science industry. You can position your company as a go-to source for industry knowledge and expertise by consistently sharing valuable insights, research findings, and thought-provoking content. This enhances your reputation and builds credibility and trust amongst potential candidates, employees, patients, and other stakeholders.

• Evinova will operate as a separate health-tech business within AstraZeneca
• Evinova’s globally-scaled digital health solutions are evidence-led, science-based and human experience-driven to serve clinical trial sponsors, clinical research organisations (CROs), clinical trial site care teams and patients
• First strategic collaborations with globally-leading CROs Parexel and Fortrea enable Evinova’s digital health solutions to be offered to their wide customer base

AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. 

-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas --

Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 2023¹ to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases.